Thank you for standing by for the Alphabet fourth quarter and fiscal year 2024 earnings conference call. At this time, all ...

This is where a tech-driven hub services platform comes into the picture. Navigating the cost ... of specialty pharmacy –– from back-office and administrative tasks to the patient-facing ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Are you a current or former worker for a state governor’s office? We’d love to hear more ... UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

The drug, called Journavx (suzetrigine) and manufactured by biotech company Vertex Pharmaceuticals, is a non-opioid painkiller, which doesn’t have addictive properties, unlike opioids often used for ...

Read full article: Dog attacked by rabid skunk in Lynchburg Tinder Gold just got a whole lot cheaper — from $108 down to $39.97 Tinder Gold just got a whole lot cheaper — from $108 down to $39 ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...